Radiopharm Theranostics Ltd
RADX4.905USD
-0.120-2.41%
Cierre 06/06, 16:00（ET）Cotizaciones retrasadas 15 min
--Cap. mercado
--P/E TTM
Más Datos de Radiopharm Theranostics Ltd Compañía
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
Información de la empresa
Código de la empresaRADX
Nombre de la empresaRadiopharm Theranostics Ltd
Fecha de salida a bolsaNov 25, 2021
Fundada en2021
Director ejecutivoMr. Riccardo Canevari
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscal- -
DirecciónLevel 3
CiudadMELBOURNE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísAustralia
Código postal3053
Teléfono61398245254
Sitio Webhttps://radiopharmtheranostics.com/
Código de la empresaRADX
Fecha de salida a bolsaNov 25, 2021
Fundada en2021
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul Hopper
Mr. Paul Hopper
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ian Turner
Mr. Ian Turner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Thomas H. (Thom) Tulip, Ph.D.
Dr. Thomas H. (Thom) Tulip, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Dimitris Voliotis, M.D.
Dr. Dimitris Voliotis, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Phillip Hains
Mr. Phillip Hains
Chief Financial Officer, Executive Officer, Company Secretary
Chief Financial Officer, Executive Officer, Company Secretary
--
--
Ms. Hester Larkin
Ms. Hester Larkin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Riccardo Canevari
Mr. Riccardo Canevari
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul Hopper
Mr. Paul Hopper
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ian Turner
Mr. Ian Turner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Thomas H. (Thom) Tulip, Ph.D.
Dr. Thomas H. (Thom) Tulip, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Dimitris Voliotis, M.D.
Dr. Dimitris Voliotis, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: dom., 23 de feb
Hora de actualización: dom., 23 de feb
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
SilverArc Capital Management, LLC
2.41%
Regal Partners Limited
1.17%
Regal Funds Management Pty. Ltd.
1.17%
Affinity Asset Advisors LLC
0.83%
Other
94.42%
Estadísticas de accionistas
Accionista
Proporción
SilverArc Capital Management, LLC
2.41%
Regal Partners Limited
1.17%
Regal Funds Management Pty. Ltd.
1.17%
Affinity Asset Advisors LLC
0.83%
Other
94.42%
Tipo
Accionista
Proporción
Hedge Fund
4.41%
Investment Advisor
1.17%
Other
94.42%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
5
526.71K
6.77%
+526.71K
2024Q4
5
526.71K
6.77%
+526.71K
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
SilverArc Capital Management, LLC
187.41K
2.41%
+187.41K
--
Dec 31, 2024
Regal Partners Limited
90.91K
1.17%
+90.91K
--
Dec 31, 2024
Regal Funds Management Pty. Ltd.
90.91K
1.17%
+90.91K
--
Dec 31, 2024
Affinity Asset Advisors LLC
156.17K
2.01%
+156.17K
--
Dec 31, 2024
UBS Financial Services, Inc.
1.32K
0.02%
+1.32K
--
Dec 31, 2024
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
